Stéphane Champiat, MD, PhD, Talks Benefits With and Next Steps for SOT101 and Pembrolizumab

During the American Association for Cancer Research (AACR) 2022 Annual Meeting, CancerNetwork® spoke with Stéphane Champiat, MD, PhD, assistant professor at the Drug Development Department of Gustave Roussy Cancer Campus in Paris, France, about the phase 2 AURELIO-3 trial (NCT04542057), which examined SOT101, an interleukin (IL)–2/IL-15 superagonist, in combination with pembrolizumab (Keytruda). Patients with solid tumors who were treated with the combination experienced acceptable safety outcomes and highly promising efficacy signals. Champiat also mention the AURELIO-04 study (NCT05256381) which is underway to test SOT101 plus pembrolizumab in solid tumors.

Transcript:

IL [interleukin]-15 is a cytokine that activates NK [natural killer] cells and CD8-positive T cells. Therefore, this dual activation of innate and adaptive immunity is suggesting that we should use this component in various tumor types. The combination here with pembrolizumab is trying to overcome primary or secondary resistance. Currently, we are seeing activity in different situations, including primary and secondary resistance. This is clearly suggesting that this compound has a promising future in monotherapy or in combination in different indications.

There is a phase 2 [trial] that is currently being prepared, which would be the AURELIO-04 study using SOT101, the IL-15 superagonist, in combination with pembrolizumab in different tumor types, including non–small cell lung cancer, colorectal cancer, cutaneous squamous cell carcinoma, hepatocellular carcinoma, prostate cancer, and ovarian cancer.

Reference

Champiat S, Marabelle A, Galvao V, et al. SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: interim safety and efficacy results from the AURELIO-03 dose escalation trial. Presented at the 2022 American Association for Cancer Research Annual Meeting. New Orleans, LA. April 8-13, 2022.